AlphaStocks
7.8
Strong Buy

AbbVie Inc. (ABBV)

As of Sep 20, 2026, AbbVie Inc. (ABBV) scores 7.8/10 on AlphaStocks' five-model composite, #2 of 168 Health Care stocks. At $264, ABBV trades 102% above its model fair value of $131.

Health Care / Biotechnology

S&P 500

$263.86

Above average across most dimensions. A solid candidate.

Strong Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#2out of 168 in Health Care

Is AbbVie Inc. a Good Investment in 2026?

AbbVie Inc. (ABBV) scores 7.8 out of 10 on AlphaStocks' composite model, earning a Strong Buy rating. The Piotroski model rates AbbVie Inc. as Strong (9/9). The Greenblatt Magic Formula model is the least favorable, rating it Neutral. AbbVie Inc. currently trades 102% above its estimated fair value of $131. AbbVie Inc. ranks #2 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E110.7ROE-143.0Market Cap468BDiv Yield2.7

Estimated Fair Value

$130.53102% above

Trading above estimated fair value. P/e of 111x implies high growth expectations. eps growth of -1% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Earnings yield 3.0% · ROC 37%

Frequently Asked Questions

Is AbbVie Inc. (ABBV) a good investment?
As of Sep 20, 2026, AbbVie Inc. (ABBV) scores 7.8/10 on AlphaStocks' five-model composite, #2 of 168 Health Care stocks. At $264, ABBV trades 102% above its model fair value of $131. That score is above average across most investment dimensions.
What is AbbVie Inc.'s Piotroski F-Score?
AbbVie Inc.'s Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ABBV overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $131, ABBV appears overvalued. The stock currently trades 102% above its estimated fair value. Trading above estimated fair value. P/e of 111x implies high growth expectations. eps growth of -1% may not justify the premium.
How does ABBV compare to other Health Care stocks?
AbbVie Inc. ranks #2 out of 168 stocks in the Health Care sector, placing it in the top 1% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about ABBV?
AlphaStocks evaluates ABBV using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 7.8/10.

Similar Stocks

INCYHRMYHALO

Compare ABBV with

ABBV vs INCYABBV vs HRMYABBV vs HALO

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer